| Literature DB >> 35509956 |
Sanyukta Gurung1, Narayan Bahadur Mahotra1, Lava Shrestha1, Aakash Sherpali2, Surya Prakash Joshi2, Gambhir Shrestha3, Shailesh Shrestha4, Aman Shakya1, Manoj Kandel5.
Abstract
Objectives: Recent studies after the outbreak of coronavirus disease 2019 have shown an association of the ABO blood group to the susceptibility of severe acute respiratory syndrome coronavirus 2 infection. Anti-A and anti-B antibodies, carbohydrate clustering, interleukin-6 levels and host transmembrane protease serine subtype 2 were suggested to cause the variable susceptibility of severe acute respiratory syndrome coronavirus 2 infection to the ABO blood groups. This study aims to find the association of the ABO blood group with severe acute respiratory syndrome coronavirus 2 infection susceptibility in Nepal.Entities:
Keywords: ABO blood group; coronavirus disease 2019; disease susceptibility; severe acute respiratory syndrome coronavirus 2
Year: 2022 PMID: 35509956 PMCID: PMC9058330 DOI: 10.1177/20503121221095413
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Characteristics of the participants (n = 1091).
| Characteristics | Case | Control | ||
|---|---|---|---|---|
| n | % (95% CI) | n | % | |
| ABO blood group | ||||
| A | 291 | 26.7 (24.1–29.4) | 616 | 28.2 |
| B | 293 | 26.9 (24.2–29.6) | 661 | 29.8 |
| AB | 126 | 11.5 (9.7–13.6) | 186 | 8.5 |
| O | 381 | 34.9 (32.1–37.8) | 729 | 33.4 |
| Total | 1091 | 100.0 | 2182 | 100.0 |
CI: confidence interval.
Distribution and duration of symptoms among the cases in accordance with ABO blood group.
| Characteristics | ABO blood group | ||||
|---|---|---|---|---|---|
| A, n (%) | B, n (%) | AB, n (%) | O, n (%) | Total, n (%) | |
| Symptomatic | 240 (82.5) | 228 (77.8) | 99 (78.6) | 310 (81.4) | 877 (80.4) |
| Asymptomatic | 51 (17.5) | 65 (22.2) | 27 (21.4) | 71 (18.6) | 214 (19.6) |
| Duration of symptoms (days) | |||||
| 1–3 | 44 (15.1) | 51 (17.4) | 23 (18.3) | 52 (13.6) | 170 (15.6) |
| 4–10 | 127 (43.6) | 115 (39.2) | 50 (39.7) | 183 (48) | 475 (43.5) |
| >10 | 69 (23.7) | 62 (21.2) | 26 (20.6) | 75 (19) | 232 (21.3) |
| Duration of hospital stay (days) | |||||
| 1–3 | 4 (1.4) | 3 (1.0) | 1 (0.8) | 3 (0.8) | 11 (1.0) |
| 4–10 | 11 (3.8) | 6 (2.0) | 5 (4.0) | 12 (3.1) | 34 (3.1) |
| >10 | 19 (6.5) | 14 (4.8) | 6 (4.8) | 13 (3.4) | 52 (4.8) |
| Duration of ICU stay (days) | |||||
| 1–3 | 1 (0.3) | 0 (0.0) | 1 (0.8) | 1 (0.3) | 3 (0.3) |
| 4–10 | 3 (1.0) | 4 (1.4) | 3 (2.4) | 2 (0.5) | 12 (1.1) |
| >10 | 2 (0.7) | 3 (1.0) | 0 (0.0) | 4 (1.0) | 9 (0.8) |
ICU: intensive care unit.
ABO blood group distribution difference between case and control groups.
| ABO blood groups | ||||
|---|---|---|---|---|
| A | B | AB | O | |
| Control, n (%) | 616 (28.2%) | 651 (29.8%) | 186 (8.5%) | 729 (33.4%) |
| Case, n (%) | 291 (26.7%) | 293 (26.9%) | 126 (11.5%) | 381 (34.9%) |
| χ2 | 0.88 | 3.15 | 7.72 | 0.74 |
| p-value | 0.35 | 0.08 | 0.005 | 0.39 |
| OR | 0.93 | 0.86 | 1.40 | 1.07 |
| 95% CI | 0.79–1.09 | 0.73–1.02 | 1.10–1.78 | 0.92–1.25 |
OR: odds ratio; CI: confidence interval.